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Introduction: The burden of cervical cancer is large and growing in developing countries,
due in large part to limited access to screening services and lack of human papillomavirus
(HPV) vaccination. In spite of modern advances in diagnostic and therapeutic modalities,
outcomes from cervical cancer have not markedly improved in recent years. Novel clinical
trials are urgently needed to improve outcomes from cervical cancer worldwide.
Methods: The Cervix Cancer Research Network (CCRN), a subsidiary of the Gynecologic
Cancer InterGroup, is a multi-national, multi-institutional consortium of physicians and sci-
entists focused on improving cervical cancer outcomes worldwide by making cancer clinical
trials available in low-, middle-, and high-income countries. Standard operating procedures
for participation in CCRN include a pre-qualifying questionnaire to evaluate clinical activi-
ties and research infrastructure, followed by a site visit. Once a site is approved, they may
choose to participate in one of four currently accruing clinical trials.
Results: To date, 13 different CCRN site visits have been performed. Of these 13 sites
visited, 10 have been approved as CCRN sites including Tata Memorial Hospital, India;
Bangalore, India; Trivandrum, India; Ramathibodi, Thailand; Siriaj, Thailand; Pramongkutk-
lao,Thailand; Ho Chi Minh, Vietnam; Blokhin Russian Cancer Research Center; the Hertzen
Moscow Cancer Research Institute; and the Russian Scientific Center of Roentgenora-
diology. The four currently accruing clinical trials are TACO, OUTBACK, INTERLACE, and
SHAPE.
Discussion: The CCRN has successfully enrolled eight sites in developing countries to
participate in four randomized clinical trials.The primary objectives are to provide novel ther-
apeutics to regions with the greatest need and to improve the validity and generalizability
of clinical trial results by enrolling a diverse sample of patients.
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INTRODUCTION
Cervical cancer is the fourth most common cancer in women
worldwide with almost 530,000 cases diagnosed in 2012 (1). Of
these, nearly 85% of cases occur in developing countries, due
in large part to limited access to screening services and lack of
human papillomavirus (HPV) vaccination (2). Lack of screening
also leads to diagnosis at advanced stages of disease and with clini-
cally debilitating symptoms. Even more concerning, nearly 90% of
the estimated 270,000 deaths from cervical cancer in 2012 occurred
in developing countries (1), suggesting that cancer diagnosis and
treatment services are inadequate in regions of the world with the
highest incidence of the disease. Furthermore, cervical cancer dis-
proportionately affects young women, and loss of life attributable
to advanced cancer has significant social and economic impact on
individual families, as well as societies at large (3–5).
Treatment for cervical cancer can include surgery, chemother-
apy, radiotherapy, or a combination of these treatments depending
on the stage at cancer diagnosis (6). For locally advanced disease,
concurrent chemoradiation followed by brachytherapy has been
the standard of care in developed nations for decades based on
the results of several large, randomized clinical trials showing
improvement in survival with the addition of chemotherapy to
radiotherapy (7–10). However, in spite of recent advances in
imaging, chemotherapy administration, and radiotherapy plan-
ning and delivery, outcomes from cervical cancer have not
markedly improved, even in developed countries where the most
cutting-edge therapies are readily available (11).
Novel treatment strategies are urgently needed to improve out-
comes from cervical cancer. One challenge to novel therapy devel-
opment is that clinical trials are often conducted in high-income
countries where research resources are the greatest; however, the
incidence of cervical cancer is lowest. Furthermore,outcomes from
clinical trials conducted in high-income countries may not be gen-
eralizable to low- and middle-income countries, which face unique
challenges in cancer treatment accessibility and administration.
Partnership between clinicians and researchers in developing and
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developed nations is vital to generating treatment paradigms with
worldwide applicability and efficacy.
Cancer clinical trial access is scare in many developing coun-
tries, as the research support and infrastructure needed to enroll
patients is often unavailable. The Cervix Cancer Research Net-
work (CCRN), a subsidiary of the Gynecologic Cancer InterGroup
(GCIG), is a multi-national, multi-institutional consortium of
physicians and scientists focused on improving cervical cancer
outcomes worldwide by making cancer clinical trials available in
low-, middle-, and high-income countries. In this manuscript, we
describe the early activities of the CCRN, with a focus on describ-
ing a model of collaborative capacity-building, with the overall
goal of promoting cervical cancer research and improving access
to novel therapies.
MATERIALS AND METHODS
HISTORY
The CCRN is a subsidiary of the GCIG, a non-profit network of
appointed representatives from international cooperative research
groups for clinical trials in gynecologic cancers. The GCIG was
established in 1990s with the goal of promoting and conduct-
ing high quality clinical trials to improve outcomes for women
with cancers of the ovary, uterus, and cervix. The GCIG has been
highly successful in completing clinical trials, publishing results,
and developing consensus conferences.
The CCRN developed to address the lack of cervical cancer
clinical trials, increase enrollment on existing trials, and improve
the standards of cancer care in low- and middle-income countries.
In light of the limited improvement in survival in locally advanced
cervical cancer in the decades since chemoradiation became the
standard of care, the vision of the CCRN was to provide infrastruc-
ture and support for cancer clinical trials in developing nations
that have a significant burden of cervical cancer.
GOVERNANCE
The CCRN reports to and is guided by the Executive Board of
Directors of the GCIG. This Board has regularly scheduled tele-
conferences and semi-annual meetings. The chair and co-chair of
the CCRN are elected for 3-year terms by voting members. The
chair of the CCRN serves on the Executive Board of the GCIG and a
formal report of activities and progress is made to the membership
at the General Assembly at each semi-annual meeting.
EARLY DEVELOPMENT
The mission of the CCRN was formulated by the committee
chair and participating members. The literature was evaluated
for best practices for clinical trials within gynecologic cancers,
with emphasis on methods for low- and middle-income coun-
tries in which clinical trial resources are often limited. The CCRN
then developed standard operating procedures (SOP) to evaluate
potential participating sites to ensure appropriate infrastructure
prior to clinical trial enrollment. The principal investigators of the
CCRN trials normally select potential sites. The SOP workflow is
demonstrated in Figure 1.
FIGURE 1 | Workflow for CCRN site approval.
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The SOP includes a pre-qualifying questionnaire to evaluate
clinical activity, site resources, clinical trials infrastructure, radi-
ation therapy treatment records, radiotherapy quality assurance,
and clinical management documentation (Table 1). Additionally,
participation in a radiotherapy beam measurement program is
required every 2 years to determine the stability of the output of
linear accelerators from each participating center. This is typically
done with thermal luminescent dosimetry or more recently, opti-
cally stimulated luminescent dosimetry. With support from the
National Cancer Institute of the United States, the Imaging and
Radiation Oncology Core in Houston, TX, USA, has been instru-
mental in partnering with the CCRN to provide quality assurance
checks.
For potential study sites deemed eligible after the pre-qualifying
survey, a site visit must be performed by an audit team to eval-
uate the appropriateness and readiness to participate in CCRN
trials. Infrastructure, the physical plant, and human resources are
evaluated to ensure that clinical trial participation can succeed.
The audit team typically includes one clinical specialist and one
clinical trials manager. Various measures of quality assurance are
performed, depending on the requirements of the available clinical
Table 1 | Pre-qualifying questionnaire.
Assessment category Question
Clinical volume • Average number of new cancer patients
seen per year?
• Average number of new gynecologic cancer
patients seen per year?
• Average number of new cervix cancer
patients seen per year?
Pathology/hematology
resources
Availability of the following resources on site
(yes/no)
• Routine hematology
• Routine biochemistry
• Routine anatomic pathology
• Long-term specimen storage
• Designated gynecologic pathologist
• Specialized pathology services
• Transfusion facility
• Critical care facility
Radiology Resources Availability of the following resources on site
(yes/no)
• Plane X-ray
• Ultrasound
• Computed Tomography (CT)
• Positron-Emission Tomography (PET)
• Magnetic Resonance Imaging (MRI)
• PET/CT
• Dedicated gynecologic radiologist
Technology support • Email available during working hours?
• Access to computers for doctors,
technologists, data managers, and nurses?
• Is the facility capable of digital data exchange?
trial. To date, the CCRN has received limited funding from the
International Gynecologic Cancer Society (IGCS) and the GCIG,
as well as support from the NCI.
RESULTS
To date, 13 different CCRN site visits have been performed. Of
these 13 sites visited, 10 have been approved as CCRN sites includ-
ing Tata Memorial Hospital, India; Bangalore, India; Trivandrum,
India; Ramathibodi, Thailand; Siriaj, Thailand; Pramongkutk-
lao, Thailand; Ho Chi Minh, Vietnam; Blokhin Russian Cancer
Research Center; the Hertzen Moscow Cancer Research Institute;
and the Russian Scientific Center of Roentgenoradiology. Approval
with contingencies has been granted to sites in Cluj, Romania, and
Minsk, Belarus.
Through significant efforts within the Cervix Cancer Com-
mittee at the GCIG, four multi-national cervical cancer clinical
trials suitable for both developed and developing nations have
successfully been opened.
1. The Tri-weekly Administration of Cisplatin in LOcally
Advanced Cervical Cancer Trial (TACO Trial), developed by
investigators from the Korean Gynecologic Oncology Group
(KGOG) and the Thai Cooperative Group, is a random-
ized phase III study that compares weekly chemotherapy
for advanced cervix cancer to every-3-week chemotherapy.
Preliminary data from a phase II trial by the KGOG sug-
gest that every-3-week chemotherapy may confer a survival
benefit (12).
2. The OUTBACK Trial is led by investigators from the Aus-
tralia/New Zealand Gynecologic Oncology Group (ANZGOG).
This study is a randomized phase III trial evaluating the efficacy
of extended adjuvant chemotherapy in women with advanced
cervix cancer compared to the standard of weekly cisplatin
chemotherapy and definitive radiotherapy. The OUTBACK
chemotherapy consists of four cycles of carboplatin and pacli-
taxel chemotherapy administered after standard concurrent
chemoradiotherapy. The rationale for the study is a meta-
analysis of several studies that showed adjuvant chemotherapy
to be a promising approach (13).
3. The INTERLACE Trial is headed by the National Can-
cer Research Institute (NCRI) from the United Kingdom.
This is a randomized phase III study evaluating neoadju-
vant chemotherapy prior to concurrent chemoradiotherapy
for women with advanced cervix cancer compared to con-
current chemoradiotherapy alone. The goal of this study is
to improve compliance with additional chemotherapy by giv-
ing it before standard chemoradiotherapy, as opposed to after
standard chemoradiotherapy.
4. The SHAPE Trial is spearheaded by investigators from the
NCIC Clinical Trials Group in Canada. This randomized
phase III trial is evaluating radical hysterectomy versus sim-
ple hysterectomy in women with early-stage cervix cancer. The
primary endpoint is freedom from pelvic failure.
Each approved CCRN site chooses to participate in one or more
of the four available clinical trials. To date, 48 patients have been
enrolled.
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DISCUSSION
The greatest burden of cervical cancer is in developing countries,
particularly parts of Africa, Central and South America, East-
ern Europe, India, and other parts of Asia (1). The outcomes
from locally advanced cancer remain suboptimal, and develop-
ment and testing of novel therapies has occurred in countries with
the lowest incidence of cervical cancer. The aim of the CCRN is to
improve access to clinical trials, enhance clinical trial enrollment
particularly in countries with high disease burden, and to produce
treatment paradigms that are applicable and accessible to women
worldwide.
There are many challenges in conducting multi-national clin-
ical trials, particularly in low-resource settings (14, 15). Human
resource training and research infrastructure development are
necessary to ensure success; however, this may entail high costs.
Rigorous quality assurance is also costly, but necessary to main-
tain the validity of the research question. Furthermore, open
and rapid communication among study coordinators, physicians,
and patients is required, but can be challenging due to language
barriers and connectivity issues. Another challenge is collabora-
tion not only with local physicians and hospitals but also with
government and insurers. As an example, the CCRN sites in
India have not been activated secondary to strict requirements
by the Indian Government for complete trial insurance, which
was too expensive to be covered by the four funded CCRN tri-
als. Finally, extraordinary care must be taken to ensure clinical
trial design and conduct is in accordance with the ethics guide-
lines set forth by the World Medical Association’s Declaration
of Helsinki and the Council for International Organization of
Medical Sciences (15).
In spite of these real and complex challenges, there are
tremendous opportunities to enhance clinical trials results and
improve cervical cancer outcomes through collaboration, creativ-
ity, and persistence. Rapid improvements in technology, particu-
larly internet-based approaches, have made communication and
quality assurance checks more feasible, timely, and cost-effective.
Investments in research training and infrastructure development
have the potential to influence not only cervical cancer clinical
trial involvement but also standard care and care for other types
of cancers. While sophisticated translational trials involving com-
plex imaging and biomarker measurement will be confined to
core GCIG settings, pragmatic trials that are aimed at defining
worldwide standard of care, as well as trials directed at practices
in low- and middle-income countries, are within the capability of
the CCRN.
In summary, the CCRN has developed a methodology to eval-
uate potential clinical trial enrollment sites in low- and middle-
income countries to make cervical cancer clinical trials available
in countries with the highest burden of disease. The CCRN has
successfully enrolled 10 sites in developing countries to partic-
ipate in four randomized clinical trials. The primary objectives
are to provide novel therapeutics to regions with the greatest
need and to improve the validity and generalizability of clini-
cal trial results by enrolling a diverse sample of patients, with
the ultimate goal of improving outcomes from cervical cancer
worldwide.
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